3 شركات بنت ثرواتها على لقاحات كوفيد، ولكن واحدة فقط لديها خطة حقيقية لما يأتي بعد ذلك

-
Moderna (MRNA) generated $1.944B in full-year 2025 revenue (down 39.2% YoY) with negative $2.822B net loss and negative $2.065B free cash flow, settling a $2.25B patent dispute while trading 13.6% above the $43.75 Wall Street consensus target. Novavax (NVAX) posted profitable results with $0.11 EPS versus negative $0.42 estimates and $147.14M revenue (up 66.6% YoY) driven heavily by Sanofi partnership, though it carries negative shareholder equity and high volatility (beta 2.63). BioNTech (BNTX) reported positive full-year 2025 revenue growth of 4.3% to €2.87B with €17.2B in cash and positive €403M operating cash flow, with 14 analyst Buys and a consensus target of $130.72, implying 52.4% upside from the current price.
-
The COVID-19 vaccine boom created unsustainable revenue models for all three companies, forcing Moderna and BioNTech to pivot toward oncology while Novavax depends on partnerships for survival, with only BioNTech positioned to fund a multi-year transition backed by a fortress balance sheet and pipeline breadth.
-
A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here.
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same period, still below its pandemic peak. Novavax (NASDAQ: NVAX) has lost 95.3% in five years. The central question for any investor holding or considering these names: which company has a credible, executable plan for what comes next?
Moderna is the best-performing large-cap healthcare stock year to date, up 67.7% YTD and 58.9% over the past year. That is real momentum. The problem is what sits underneath it.
Full-year 2025 revenue came in at $1.944 billion, down 39.23% year over year. The net loss was $2.822 billion, and free cash flow ran at negative $2.065 billion. The company recently settled a major patent dispute for $2.25 billion, with $950 million due upfront, clearing an IP overhang but landing a significant blow to a cash position that already required drawing $600 million on a $1.5 billion credit facility. Management guides for year-end cash of $5.5 billion to $6.0 billion, assuming up to 10% revenue growth.
Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement
Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.
The pipeline is ambitious: a flu-COVID combo vaccine is under EMA review, a personalized cancer vaccine developed with Merck showed a 49% reduction in recurrence or death versus Keytruda alone in melanoma, and a norovirus vaccine has completed Phase 3 enrollment. But the FDA issued a refusal-to-file on the standalone flu vaccine, and forward EPS remains negative $7.10. Wall Street consensus is 18 Holds, three Sells, and only three Buys, with an analyst target of $43.75 against a current price of $49.69. The stock has already priced in a recovery the financials have not yet delivered.
Novavax is the only one of the three currently profitable. Its most recent quarter posted EPS of $0.11, beating estimates of negative $0.42 by 126.15%. Revenue rose 66.61% year over year to $147.14 million, driven largely by Sanofi partnership, which contributed $98 million of that total.
The technology story is real. Novavax's Matrix-M adjuvant is licensed to Pfizer for up to $500 million in milestones following a $30 million upfront payment. Its R21 malaria vaccine holds over 80% market share with 30 million doses sold. Forward EPS is $2.46, the only positive forward earnings figure in this group.
The risks are hard to ignore. Stockholder equity is negative $127.753 million. The company depends heavily on Sanofi forecasts and the Serum Institute of India for manufacturing. Its beta is 2.63, the most volatile of the three. Wall Street is deeply split: five Buys but two Strong Sells and on Sell. The five-year bear case price target is $7.10, below where the stock trades today. Novavax has survived, though its path to sustainable growth beyond its current partnerships remains undefined.
BioNTech is down 10.3% year to date and 22.5% over the past month, trading well below its 52-week high of $124. The underlying setup diverges from the recent price action.
BioNTech holds €17.2 billion (approximately $19.4 billion USD) in cash and €17.0 billion ($19.2 billion USD) $billion in shareholders equity, generating positive operating cash flow of €403 million ($456 million USD) in 2025, giving it a revenue base to fund the pivot. Full-year 2025 revenue grew 4.3% year over year to €2.87 billion (approx. $3.25 billion USD), the only one of the three to post revenue growth.
The oncology pipeline is the real argument. Pumitamig has 8 global Phase 3 trials planned by year-end 2026 in partnership with Bristol Myers Squibb across more than 10 tumor types. A BLA submission for trastuzumab pamirtecan in HER2-positive endometrial cancer is planned for 2026. Analyst conviction has followed: 14 Buys, zero Sells, with a consensus target of $130.72 against a current price of $85.86—meaningful implied upside from analysts not known for generosity toward post-COVID biotech names.
The co-founder departure is a genuine risk. Ugur Sahin and Ozlem Tureci are transitioning out by end of 2026 to lead a separate mRNA venture. Leadership transitions at founder-led biotechs carry real execution risk. But the balance sheet is strong enough to absorb setbacks, the pipeline broad enough to deliver multiple readouts, and the valuation at a forward P/E of 7x prices in minimal success.
All three companies built their businesses on COVID and are paying the price of that dependency. Moderna has momentum but is burning cash and trading above analyst targets. Novavax is profitable but small, volatile, and structurally fragile. BioNTech has the balance sheet to fund a multi-year oncology pivot, the market share to sustain revenue while it does, and the strongest analyst conviction of the group—at a valuation that reflects skepticism rather than optimism. Among the three, BioNTech has the balance sheet, pipeline breadth, and analyst conviction that analysts cite most frequently when discussing post-COVID biotech exposure.
Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.
And no, it’s got nothing to do with increasing your income, savings, clipping coupons, or even cutting back on your lifestyle. It’s much more straightforward (and powerful) than any of that. Frankly, it’s shocking more people don’t adopt the habit given how easy it is.